| scholarly article | Q13442814 |
| P2093 | author name string | Tartaglia J | |
| Brunet S | |||
| Leroy V | |||
| Audonnet JC | |||
| Desmettre P | |||
| Minke J | |||
| Poulet H | |||
| Guiot AL | |||
| Boularand C | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vaccine | Q134808 |
| leukemia | Q29496 | ||
| vector-borne disease | Q2083837 | ||
| Canarypox virus | Q2936179 | ||
| P304 | page(s) | 141-145 | |
| P577 | publication date | 2003-08-01 | |
| P1433 | published in | Veterinary Record | Q7923713 |
| P1476 | title | Efficacy of a canarypox virus-vectored vaccine against feline leukaemia | |
| P478 | volume | 153 |
| Q40423412 | A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse |
| Q37547454 | A targeted mutation within the feline leukemia virus (FeLV) envelope protein immunosuppressive domain to improve a canarypox virus-vectored FeLV vaccine. |
| Q37288017 | Antigen delivery systems for veterinary vaccine development. Viral-vector based delivery systems |
| Q28304570 | Avipoxviruses: infection biology and their use as vaccine vectors |
| Q37616773 | Bluetongue vaccines. |
| Q57697521 | Cellular segregation of feline leukemia provirus and viral RNA in leukocyte subsets of long-term experimentally infected cats |
| Q51789014 | Comparing the efficacy of FeLV vaccines: comment on: Stuke, K. et al. Efficacy of an inactivated FeLV vaccine compared to a recombinant FeLV vaccine in minimum age cats following virulent FeLV challenge. Vaccine 2014;32(22):2599-603. |
| Q35586830 | DNA vaccines in veterinary use. |
| Q36709731 | Development and registration of recombinant veterinary vaccines. The example of the canarypox vector platform |
| Q42229396 | Efficacy of an inactivated FeLV vaccine compared to a recombinant FeLV vaccine in minimum age cats following virulent FeLV challenge |
| Q38032360 | Feline leukaemia virus: half a century since its discovery |
| Q43157185 | Immunosuppression in a Comparative Study of Feline Leukemia Virus Vaccines |
| Q41474263 | No benefit of therapeutic vaccination in clinically healthy cats persistently infected with feline leukemia virus |
| Q37207640 | Phylogenetic analysis of three genes of Penguinpox virus corresponding to Vaccinia virus G8R (VLTF-1), A3L (P4b) and H3L reveals that it is most closely related to Turkeypox virus, Ostrichpox virus and Pigeonpox virus. |
| Q35851786 | Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors |
| Q34431934 | Protection of Sheep against Rift Valley Fever Virus and Sheep Poxvirus with a Recombinant Capripoxvirus Vaccine |
| Q33384790 | Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus |
| Q45410795 | Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep |
| Q43157188 | Reply to "Immunosuppression in a Comparative Study of Feline Leukemia Virus Vaccines". |
| Q37175177 | Targeted strategies for henipavirus therapeutics |
| Q26995905 | The evolution of poxvirus vaccines |
| Q45408088 | Vaccination against the feline leukaemia virus: outcome and response categories and long-term follow-up |
| Q38220140 | Viral causes of feline lymphoma: retroviruses and beyond |
Search more.